Volume | 1,968,789 |
|
|||||
News | - | ||||||
Day High | 12.4555 | Low High |
|||||
Day Low | 10.92 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
KalVista Pharmaceuticals Inc | KALV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.08 | 10.92 | 12.4555 | 11.07 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
13,294 | 1,968,789 | $ 11.80 | $ 23,226,457 | - | 6.60 - 16.88 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:49:56 | 100 | $ 11.855 | USD |
KalVista Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
502.46M | 42.19M | - | 0 | -92.91M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
KalVista Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KALV Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.30 | 12.70 | 10.70 | 11.38 | 370,305 | -0.445 | -3.62% |
1 Month | 13.58 | 14.62 | 10.70 | 12.95 | 554,244 | -1.73 | -12.70% |
3 Months | 12.13 | 16.88 | 10.70 | 13.89 | 804,123 | -0.275 | -2.27% |
6 Months | 9.84 | 16.88 | 7.21 | 12.43 | 553,820 | 2.02 | 20.48% |
1 Year | 6.63 | 16.88 | 6.60 | 11.67 | 385,190 | 5.23 | 78.81% |
3 Years | 28.01 | 30.70 | 4.12 | 12.60 | 313,530 | -16.16 | -57.68% |
5 Years | 28.26 | 45.00 | 4.12 | 16.71 | 281,542 | -16.41 | -58.05% |
KalVista Pharmaceuticals Description
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. |